Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) - A Double Blind, Randomized, Placebo-controlled, Multicenter Trial
Phase of Trial: Phase I/II
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Tacrolimus (Primary)
- Indications Epistaxis
- Focus Therapeutic Use
- Acronyms TACRO
- 07 Dec 2018 Status changed from recruiting to completed.
- 21 Jul 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2017 New trial record